AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Sialidase-2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library is unique due to several crucial aspects:

  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q9Y3R4

UPID:

NEUR2_HUMAN

Alternative names:

Cytosolic sialidase; N-acetyl-alpha-neuraminidase 2

Alternative UPACC:

Q9Y3R4; Q3KNW4; Q6NTB4

Background:

Sialidase-2, also known as cytosolic sialidase or N-acetyl-alpha-neuraminidase 2, plays a crucial role in the catabolism of glycolipids, glycoproteins, and oligosaccharides. It specifically catalyzes the hydrolytic cleavage of terminal sialic acids, displaying a preference for certain sialylated gangliosides. This enzyme's activity varies based on the sialyl linkage positions and the supramolecular organization of sialoglycoconjugates.

Therapeutic significance:

Understanding the role of Sialidase-2 could open doors to potential therapeutic strategies. Its specific enzymatic function in the metabolism of sialoglycoconjugates suggests a foundational role in cellular processes, hinting at its potential as a target in therapeutic interventions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.